View in EDS HTML Full Text PDF Full Text

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Saved in:
Bibliographic Details
Title: Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
Authors: Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Ieguchi K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Shimizu T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan., Suzuki R; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Mura E; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ikeda G; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Shimokawa M; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Yoshimura K; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Showa Medical University Comprehensive Cancer Information Center, Showa Medical University, Tokyo 142-8555, Japan., Tsuji M; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan., Oguchi T; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo 142-8555, Japan., Kiuchi Y; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo 157-8577, Japan.; Department of Pharmacology, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa Medical University, Tokyo 142-8555, Japan.
Source: Cancers [Cancers (Basel)] 2025 Jul 18; Vol. 17 (14). Date of Electronic Publication: 2025 Jul 18.
Publication Type: Journal Article
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2072-6694
DOI:10.3390/cancers17142384